ERBB2 and breast cancer: Low nuclear DARPP-32 expression was significantly associated with adverse progression-free survival of HER2 positive breast cancer patients treated with trastuzumab (P = 0.031) (Fig. 3A); cytoplasmic DARPP-32 expression was not associated with progression-free survival (data not shown).